23 June 2018

Superior blood sugar control for both Hispanic and non-Hispanic patients with Soliqua® vs insulin glargine 100 Units/ml

BackgroundClinical & psychological consequences of poor blood sugar control
As the number of people around the world with type 2 diabetes increases, there is a need for treatments that limit periods with high blood sugar, while also minimizing low blood sugar incidents.
Extended periods of high blood sugar can lead to serious long-term complications such as cardiovascular disease.
Experiencing a severe low blood sugar event that requires help from someone else can have an important psychological impact on a patient. It might reduce their motivation to stick to their prescribed treatment plan and could even lead them to stop treatment altogether. Either of these decisions could have a substantial impact on their long-term health outcomes.
With its long-standing commitment to addressing the needs of people with diabetes, Sanofi has continued its extensive research program comparing the effectiveness of different long-acting insulins to treat people with diabetes. Sanofi is presenting the following new analysis at the American Diabetes Association (ADA) 78thScientific Sessions in Orlando, Florida, U.S.

Switching to Toujeo® reduces long-term blood sugar with low incidence of low blood sugar events in adults with type 2 diabetes
*     Observational study tracks clinical improvements for 12 months after switching to Toujeo

Switching treatment toToujeo® (insulin glargine 300 Units/mL) from other long-acting insulins reduces rates of low blood sugar events (hypoglycemia) at any time of day, and particularly at night, in adults with type 2 diabetes. These results, from a prospective observational analysis of real-world data for patients in Germany, were presented today at the American Diabetes Association (ADA) 78th Scientific Sessions in Orlando, Florida, U.S.

The study also showed reductions in long-term blood sugar (HbA) and in overnight blood sugar (fasting plasma glucose, FPG) 6 months after switching to Toujeo from other long-acting insulins, which was more pronounced after 12 months.

“For people with type 2 diabetes who are uncontrolled on their current treatment, TOP-2 demonstrates the potential of Toujeo to manage the delicate balance of reducing blood sugar levels while lowering the risk of low blood sugar events,” says Mourad Behar, Head of Medical Affairs, Europe Diabetes, Sanofi. “Evidence from this real-world observational study shows that treatment benefits seen after 6 months are sustained to 12 months, and will inform physicians’ decisions on appropriate treatments for their patients with type 2 diabetes.”

The TOP-2 study, together with previous studies from the EDITION and DELIVER programs, consistently demonstrate reductions in risk of low blood sugar for patients with type 2 diabetes versus other generation long-acting insulins. The lower risk of low blood sugar versus insulin glargine 100 Units/mL has been confirmed in multiple clinical trials. Studies have also demonstrated the more stable profile of Toujeo versus insulin glargine 100 Units/mL, and the flatter profile with fewer within-day fluctuations of Toujeo versus insulin degludec.

No comments:

Post a Comment

CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies

Copyright © Noticia de Salud